Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Biotechnology

Healthcare
$61.99 -1.39%

-$0.46 today

Market cap
$1.79B
Beta
0.89
P/E (TTM)
-597.6
EPS (TTM)
-$0.05
52W Low $13.09High $35.66

Volume 0.48M

Average 0.43M

Returns on capital

Eton Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-17.6%

avg -64.3%

ROIC

0.1%

avg -44.0%

ROA

-5.0%

avg -40.9%

Analysis

ROIC is currently the strongest return metric at 0.1% versus its period average of -44.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Sean E. Brynjelsen

President, Chief Executive Officer & DirectorUSD 1.08M54——

James R. Gruber

ConsultantUSD 740.51K54213.42K0.78%

David Krempa

Chief Business OfficerUSD 737.19K3743.38K0.16%

Ipek Erdogan-Trinkaus

Chief Commercial OfficerUSD 575.29K444.08K0.01%

Danka Radosavljevic

Chief Operating Officer—427.19K0.03%

Judith Matthews

Chief Financial Officer & Secretary—56——

Scott Grossenbach

Senior Vice President of Sales Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

33

$32.05M

Net Transaction Value

−$32.05M

Net selling

Most Active

Opaleye Management Inc.

9 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 10, 26

Erdogan-Trinkaus Ipek

Direct

Sell$157.2K
Nov 10, 26

Erdogan-Trinkaus Ipek

Direct

Sell$78.7K
Nov 10, 26

CASAMENTO CHARLES J

Direct

Sell$410.4K
Nov 10, 26

CASAMENTO CHARLES J

Direct

Sell$961.3K
Nov 10, 26

CASAMENTO CHARLES J

Direct

Sell$1.5M
Nov 10, 26

CASAMENTO CHARLES J

Direct

Sell$2.3M
Nov 10, 26

CASAMENTO CHARLES J

Direct

Sell$197K
Oct 6, 26

Krempa David

Direct

Sell$229.4K
Aug 28, 26

MAIER PAUL V

Direct

Sell$811.9K
Aug 28, 26

MAIER PAUL V

Direct

Sell$7.9K

1–10 of 33

Summary

Insiders reported 0 buys worth $0.00 and 33 sells worth $32.05M over the last 12 months. That adds up to net selling of $32.05M. Opaleye Management Inc. was the most active insider with 9 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+55.5%
+46.0% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
+406.3% (5yr)2 analysts

Analysis

Recent growth has been strongest in Revenue at +55.5% over three years. Forward estimates point to EBIT at +406.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Eton Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ETON's management, answered from reported figures.

Who manages ETON?

Eton Pharmaceuticals, Inc. (ETON) lists 7 active executives. The top listed executive is David Krempa, Chief Business Officer.

Are ETON insiders buying or selling?

Recent insider activity shows net selling of $18.54M.